Press Release

New England Journal of Medicine” publishes results of MINDACT clinical trial The 70-gene test (Mammaprint®) can significantly reduce use of chemotherapy among breast cancer patients and has the potential to change clinical practice: 46% of early stage breast cancer patients classified as high-risk by traditional methods can avoid chemotherapy

Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy

APHINITY study shows Roche’s Perjeta®-based regimen reduced the risk of invasive cancer returning compared to Herceptin® and chemotherapy in HER2-positive early breast cancer

SOLE (Study of Letrozole Extension):A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer

Primary results of LORELEI study presentedat ESMO 2017 Congress

PANACEA study suggests immunotherapy may help to overcome trastuzumab-resistant breast cancer

Ovarian Suppression Reduces Recurrence for Young Breast Cancer Patients

1 out of 3 men with breast cancer does not receive adequate treatment

Belgium has the highest incidence of breast cancer in the world!

Progress in the fight against metastatic breas cancer